1. Outcome-Stratified Analysis of Biomarker Trajectories for Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2.
- Author
-
Bowring, Mary G, Wang, Zitong, Xu, Yizhen, Betz, Joshua, Muschelli, John, Garibaldi, Brian T, and Zeger, Scott L
- Subjects
- *
BIOMARKERS , *DISEASE progression , *HOSPITALS , *C-reactive protein , *GLOMERULAR filtration rate , *COVID-19 , *VITAL signs , *PATIENTS , *CASE-control method , *RETROSPECTIVE studies , *RESPIRATORY measurements , *OXYGEN saturation , *HOSPITAL admission & discharge , *CONCEPTUAL structures , *ARTIFICIAL respiration , *STATISTICAL models , *DEATH , *LONGITUDINAL method , *DISCHARGE planning , *LYMPHOCYTE count , *FIBRIN fibrinogen degradation products , *PROBABILITY theory - Abstract
Longitudinal trajectories of vital signs and biomarkers during hospital admission of patients with COVID-19 remain poorly characterized despite their potential to provide critical insights about disease progression. We studied 1884 patients with severe acute respiratory syndrome coronavirus 2 infection from April 3, 2020, to June 25, 2020, within 1 Maryland hospital system and used a retrospective longitudinal framework with linear mixed-effects models to investigate relevant biomarker trajectories leading up to 3 critical outcomes: mechanical ventilation, discharge, and death. Trajectories of 4 vital signs (respiratory rate, ratio of oxygen saturation (Sp o 2) to fraction of inspired oxygen (Fi o 2), pulse, and temperature) and 4 laboratory values (C-reactive protein (CRP), absolute lymphocyte count (ALC), estimated glomerular filtration rate, and D-dimer) clearly distinguished the trajectories of patients with COVID-19. Before any ventilation, log(CRP), log(ALC), respiratory rate, and Sp o 2-to-Fi o 2 ratio trajectories diverge approximately 8–10 days before discharge or death. After ventilation, log(CRP), log(ALC), respiratory rate, Sp o 2-to-Fi o 2 ratio, and estimated glomerular filtration rate trajectories again diverge 10–20 days before death or discharge. Trajectories improved until discharge and remained unchanged or worsened until death. Our approach characterizes the distribution of biomarker trajectories leading up to competing outcomes of discharge versus death. Moving forward, this model can contribute to quantifying the joint probability of biomarkers and outcomes when provided clinical data up to a given moment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF